744217-15-0

Upstream product

• 135911-57-8 1-[3-O-(tert-butyldimethylsilyl)-2,5-dideoxy-β-L-glycero-pent-4-enofuranosyl]thymine 
• 128070-96-2 1-(3-O-acetyl-2,5-dideoxy-β-L-glycero-pent-4-enofuranosyl)thymine 
• 499970-82-0 1-(3-O-acetyl-2,5-dideoxy-5-iodo-β-D-threo-pentofuranosyl)thymine 
• 94892-66-7 1-(2,5-dideoxy-5-iodo-β-D-threo-pentofuranosyl)thymine 
• 897037-31-9 1-[5-O-benzoyl-3-O-(tert-butyldimethylsilyl)-4-chloro-2-deoxy-β-D-threo-pentofuranosyl]thymine 
• 897037-32-0 1-[5-O-benzoyl-3-O-(tert-butyldimethylsilyl)-4-chloro-2-deoxy-α-L-erythro-pentofuranosyl]thymine 
• 744217-14-9 1-[5-O-benzoyl-3-O-(tert-butyldimethylsilyl)-2-deoxy-4-C-(trimethylsilyl)ethynyl-β-D-threo-pentofuranosyl]thymine 

Downstream Products

• 1067194-52-8 Benzoic acid (2R,3R,5R)-2-ethynyl-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3-trifluoromethanesulfonyloxy-tetrahydro-furan-2-ylmethyl ester 

Relevant academic research and scientific papers

Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections

The present invention relates to novel compounds according to the general formulas I, II, III, IV or V: wherein B is nucleoside base according to the structure: and the remaining variables as defined in the specification, and pharmaceutical compositions c

An alternative synthetic method for 4′-C-ethynylstavudine by means of nucleophilic substitution of 4′-benzoyloxythymine nucleoside

For the synthesis of 2′,3′-didehydro-3′-deoxy-4′-C- ethynylthymidine (8: 4′-Ed4T), a recently reported promising anti-HIV agent, a new approach was developed. Since treatment of 1-(2,5-dideoxy-β-l- glycero-pent-4-enofuranosyl)thymine with Pb(OBz)4 allowed

Nucleophilic substitution at the 4′-position of nucleosides: New access to a promising anti-HIV agent 2′,3′-didehydro-3′-deoxy- 4′-ethynylthymidine

For the synthesis of 2′,3′-didehydro-3′-deoxy-4′- ethynylthymidine (8: 4′-Ed4T), a recently reported promising anti-HIV agent, a new approach was developed. Since treatment of 1-(2,5-dideoxy-β-L- glyceropent-4-enofuranosyl)thymine with Pb(OBz)4

Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections

The present invention relates to novel compounds according to the to the general formulas I, II, III, IV or V: wherein B is nucleoside base according to the structure: R is H, F, Cl, Br, I, C1-C4 alkyl (preferably CH3), —C≡N, —C≡C—Ra, X is H, C1-C4 alkyl (preferably, CH3), F, Cl, Br or I; Z is O or CH2, with the proviso that Z is CH2 and not O when the compound is according to general formula II, R3 is —C≡C—H and R2 is H or a phosphate, diphosphate, triphosphate or phosphotriester group; R1 is H, an acyl group, a C1-C20 alkyl or an ether group; R2 is H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a ?group; Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety; R8 is H, or a C1-C20 alkyl or ether group, preferably a C1-C12 alkyl group; k is 0-12, preferably, 0-2; R3 is selected from a C1-C4 alkyl (preferably, CH3), —(CH2)n—C≡C—Ra, R3a and R3b are independently selected from H, F, Cl, Br or I; R4 and R5 are independently selected from H, F, Cl, Br, I, OH, C1-C4 alkyl (preferably, CH3), —(CH2)n—C≡C—Ra, ?with the proviso that R4 and R5 are not both H; Ra is H, F, Cl, Br, I, or —C1-C4 alkyl, preferably H or CH3; Y is H, F, Cl, Br, I or —C1-C4 alkyl, preferably H or CH3; and n is 0, 1, 2, 3, 4 or 5, preferably 0, 1 or 2; and their anomers, pharmaceutically acceptable salts, solvates, or polymorphs thereof.